Lung Cancer Dispatch
Follow
Find tag "ceritinib"
3.6K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

ASCO: Zykadia Works Before or After Targeted Lung Ca Tx

ASCO: Zykadia Works Before or After Targeted Lung Ca Tx | Lung Cancer Dispatch | Scoop.it

Ceritinib (Zykadia) produced good response in non-small cell lung cancer (NSCLC) overexpressing ALK, regardless of prior treatment for that target, an early phase trial showed.


Ceritinib was associated with an overall response rate of 55% in patients previously treated with crizotinib (Xalkori) and 66% in those naive to that ALK inhibitor, Dong-Wan Kim, MD, of the Seoul National University Hospital, and colleagues found.

Editor's note: This article is about a drug called ceritinib (brand name Zykadia), which was recently approved by the U.S. Food and Dug Administration (FDA), allowing doctors in the U.S. to prescribe it to patients who 1) have advanced non-small cell lung cancer (NSCLC), 2) have tumor cells with mutations in the ALK gene, as detected by molecular testing, and 3) have tried treatment with crizotinib (Xalkori) but experienced worsening of their cancer. According to the new research described in this article, ceritinib may actually be beneficial whether or not the patient was previously treated with crizotinib.
Cancer Commons's insight:

MedPage Today  |  Jun 3, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Drug Successfully Treats Crizotinib-Resistant, ALK-Positive Lung Cancer

New Drug Successfully Treats Crizotinib-Resistant, ALK-Positive Lung Cancer | Lung Cancer Dispatch | Scoop.it

"Although the targeted cancer treatment drug crizotinib is very effective in causing rapid regression of a particular form of lung cancer, patients' tumors inevitably become resistant to the drug. Now a new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer (NSCLC), both in tumors that have become resistant to crizotinib and in those never treated with the older drug. The results of a phase 1 clinical trial conducted at centers in 11 countries are reported in the March 27 New England Journal of Medicine."


Editor's note: Crizotinib and ceritinib are meant to treat patients whose tumors have mutations in the ALK gene, as detected by molecular testing.

Cancer Commons's insight:

Medical Xpress  |  Mar 26, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

FDA Approves Ceritinib (Zykadia) for Metastatic Lung Cancer

FDA Approves Ceritinib (Zykadia) for Metastatic Lung Cancer | Lung Cancer Dispatch | Scoop.it

"Earlier today the US Food and Drug Administration granted accelerated approval to ceritinib (Zykadia) for the treatment of patients with metastatic ALK-positive non–small-cell lung cancer (NSCLC). About 2% to 7% percent of NSCLC patients have ALK-positive disease.


"The new drug, a tyrosine kinase inhibitor, was approved 4 months early under the FDA's accelerated approval program and is intended for the treatment of patients who previously received the ALK-inhibitor crizotinib."


Editor's note: FDA approval means that doctors can now begin prescribing ceritinib treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors have mutations in the ALK gene, as detected by molecular testing. We previously posted about ceritinib here.

Cancer Commons's insight:

Cancer Network  |  Apr 29, 2014

more...
No comment yet.